JP2023530456A5 - - Google Patents

Info

Publication number
JP2023530456A5
JP2023530456A5 JP2022577582A JP2022577582A JP2023530456A5 JP 2023530456 A5 JP2023530456 A5 JP 2023530456A5 JP 2022577582 A JP2022577582 A JP 2022577582A JP 2022577582 A JP2022577582 A JP 2022577582A JP 2023530456 A5 JP2023530456 A5 JP 2023530456A5
Authority
JP
Japan
Prior art keywords
degrees
crystal morphology
peaks
xrpd pattern
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022577582A
Other languages
English (en)
Japanese (ja)
Other versions
JP7895867B2 (ja
JP2023530456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037535 external-priority patent/WO2021257643A1/en
Publication of JP2023530456A publication Critical patent/JP2023530456A/ja
Publication of JP2023530456A5 publication Critical patent/JP2023530456A5/ja
Priority to JP2026080975A priority Critical patent/JP2026121448A/ja
Application granted granted Critical
Publication of JP7895867B2 publication Critical patent/JP7895867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022577582A 2020-06-17 2021-06-16 Cd73阻害剤の結晶形態及びその使用 Active JP7895867B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026080975A JP2026121448A (ja) 2020-06-17 2026-05-13 Cd73阻害剤の結晶形態及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040277P 2020-06-17 2020-06-17
US63/040,277 2020-06-17
PCT/US2021/037535 WO2021257643A1 (en) 2020-06-17 2021-06-16 Crystalline forms of a cd73 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026080975A Division JP2026121448A (ja) 2020-06-17 2026-05-13 Cd73阻害剤の結晶形態及びその使用

Publications (3)

Publication Number Publication Date
JP2023530456A JP2023530456A (ja) 2023-07-18
JP2023530456A5 true JP2023530456A5 (cg-RX-API-DMAC7.html) 2024-06-24
JP7895867B2 JP7895867B2 (ja) 2026-07-28

Family

ID=76845331

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577582A Active JP7895867B2 (ja) 2020-06-17 2021-06-16 Cd73阻害剤の結晶形態及びその使用
JP2026080975A Pending JP2026121448A (ja) 2020-06-17 2026-05-13 Cd73阻害剤の結晶形態及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026080975A Pending JP2026121448A (ja) 2020-06-17 2026-05-13 Cd73阻害剤の結晶形態及びその使用

Country Status (9)

Country Link
US (2) US11649261B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168120A1 (cg-RX-API-DMAC7.html)
JP (2) JP7895867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230026312A (cg-RX-API-DMAC7.html)
CN (1) CN115942977A (cg-RX-API-DMAC7.html)
AU (1) AU2021292195A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179320A1 (cg-RX-API-DMAC7.html)
TW (1) TWI922475B (cg-RX-API-DMAC7.html)
WO (1) WO2021257643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3399984T (lt) 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
ES3070946T3 (en) * 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CA3179320A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
MX389798B (es) 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
EP3618829B1 (en) 2017-05-05 2023-06-07 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
WO2019173188A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
WO2019173682A1 (en) * 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
AU2019312296B2 (en) 2018-07-27 2025-05-29 Arcus Biosciences, Inc. Pyridone A2R antagonists
EP3880685B1 (en) 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CA3179320A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Similar Documents

Publication Publication Date Title
JP7861083B2 (ja) Fak阻害剤およびその併用薬物
CA2750413C (en) Hydroxamic acid derivatives
JP2020111618A5 (cg-RX-API-DMAC7.html)
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2016503414A5 (cg-RX-API-DMAC7.html)
JP2015512942A5 (cg-RX-API-DMAC7.html)
JP2021513965A5 (cg-RX-API-DMAC7.html)
JP2021515775A5 (cg-RX-API-DMAC7.html)
JP3200421B2 (ja) 化学療法剤としての新規ビス白金錯体
JP2024519188A5 (cg-RX-API-DMAC7.html)
JP2021531273A5 (cg-RX-API-DMAC7.html)
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
CN103848815B (zh) 含脲基片段的4-取代-6-苯基嘧啶衍生物及其制备方法和用途
CN104327050A (zh) 一种吖啶酰胺基硫脲类衍生物及其制备方法和用途
Ge et al. Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of trithe ple-negative breast cancer
Fouladdel et al. Synthesis and cytotoxicity of some biurets against human breast cancer T47D cell line
CN116057051A (zh) 白介素-1受体相关激酶1和4的抑制剂
US10111955B2 (en) PEG derivative
CN104072624B (zh) 一种多胺改性高分子药物及其制备方法与作为抗肿瘤药物的应用
CN102503908B (zh) 维a酸衍生物、其制备方法、其药物组合物及其在制备抗肿瘤药物中的应用
CN112585149B (zh) 膦过渡金属配位化合物、其制造方法和抗癌剂
CA2456550A1 (en) Tumour inhibiting cerium compounds
JP5161434B2 (ja) 抗癌剤
JP2026515180A (ja) 3-(5,7-ジフルオロ-4-オキソ-1,4-ジヒドロキノリン-2-イル)-4-(メチルスルホニル)ベンゾニトリルの結晶形態